AR101 powder provided in capsules & sachets

BIOLOGICAL3 trials

Sponsors

Aimmune Therapeutics, Inc.

Conditions

Peanut Allergy

Phase 3

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

CompletedNCT02635776

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2015-12-22End: 2018-07-02Updated: 2022-03-17

ARTEMIS Peanut Allergy In Children

CompletedNCT03201003

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2017-06-12End: 2019-02-15Updated: 2021-08-03

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

CompletedNCT03736447

Aimmune Therapeutics, Inc.Peanut Allergy

Start: 2018-12-27End: 2022-07-05Updated: 2023-03-02

Related Papers

Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial

Clinical and Translational Allergy2024-01-011 citations

Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age

NEJM Evidence2023-10-2339 citations

Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

Allergy Asthma and Clinical Immunology2023-03-134 citations

Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy

The Journal of Allergy and Clinical Immunology In Practice2021-08-1120 citations

Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.

2020-07-20101 citations

AR101 Oral Immunotherapy for Peanut Allergy

New England Journal of Medicine2018-11-18709 citations